The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Cross Shawn since 2021.
This trader's CIK number is 1734779.
At the time of last reporting, Cross Shawn was the Chief Financial Officer of Pacira Biosciences, Inc.. (stock ticker symbol PCRX).
Also see all insider trading activities at Pacira Biosciences, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | AMTI | 0 | $0 | 401,702 | $65,335 | 0 | $0 |
| 2022 | AMTI | 0 | $0 | 4,817 | $13,090 | 0 | $0 |
| 2021 | AMTI | 0 | $0 | 10,000 | $301,196 | 10,000 | $46,100 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2026 | PCRX | 0 | $0 | 25,000 | $628,192 | 25,000 | $411,249 |
| 2025 | PCRX | 0 | $0 | 37,060 | $893,155 | 25,000 | $411,249 |
1. Applied Molecular Transport Inc. (AMTI)
2. Pacira Biosciences, Inc. (PCRX)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-11-22 | AMTI | Sale | 110,802 | .16 | 18,171 |
| 2023-11-15 | AMTI | Sale | 90,447 | .16 | 14,561 |
| 2023-06-02 | AMTI | Sale | 4,306 | .24 | 1,037 |
| 2023-09-05 | AMTI | Sale | 1,253 | .21 | 260 |
| 2023-09-29 | AMTI | Sale | 193,960 | .16 | 30,839 |
| 2023-03-01 | AMTI | Sale | 934 | .50 | 467 |
| 2022-09-01 | AMTI | Sale | 884 | 1.42 | 1,255 |
| 2022-06-01 | AMTI | Sale | 1,767 | 2.97 | 5,244 |
| 2022-06-02 | AMTI | Sale | 2,166 | 3.04 | 6,591 |
| 2021-08-19 | AMTI | Sale | 300 | 30.01 | 9,003 |
| 2021-08-23 | AMTI | Option Ex | 9,700 | 4.61 | 44,717 |
| 2021-08-23 | AMTI | Sale | 9,700 | 30.12 | 292,193 |
| 2021-08-19 | AMTI | Option Ex | 300 | 4.61 | 1,383 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2026-04-23 | PCRX | Option Ex | 12,941 | 16.45 | 212,879 |
| 2026-04-23 | PCRX | Sale | 12,941 | 25.16 | 325,595 |
| 2026-04-22 | PCRX | Sale | 1,500 | 25.01 | 37,515 |
| 2026-04-21 | PCRX | Sale | 2,845 | 25.01 | 71,153 |
| 2026-04-22 | PCRX | Option Ex | 1,500 | 16.45 | 24,675 |
| 2026-04-20 | PCRX | Sale | 7,714 | 25.14 | 193,929 |
| 2026-04-21 | PCRX | Option Ex | 2,845 | 16.45 | 46,800 |
| 2026-04-20 | PCRX | Option Ex | 7,714 | 16.45 | 126,895 |
| 2025-12-09 | PCRX | Sale | 15,896 | 25.03 | 397,876 |
| 2025-12-10 | PCRX | Sale | 9,104 | 25.14 | 228,874 |
| 2025-12-09 | PCRX | Option Ex | 15,896 | 16.45 | 261,489 |
| 2025-12-10 | PCRX | Option Ex | 9,104 | 16.45 | 149,760 |
| 2025-11-10 | PCRX | Sale | 12,060 | 22.09 | 266,405 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Cross Shawn (Chief Financial Officer of Pacira Biosciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.